Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Sylvain Thepot, Simone Boehrer, MD, Thomas Prebet, Odile Beyne-Rauzy, E. Wattel, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Francois Dreyfus, Stefan Wickenhauser, Mathilde Hunault-Berger, MD, PhD, Fatiha Chermat, Pierre Fenaux, MD, PhD, Lionel Ades, MD, PhD

Blood (2012) 120 (21): 1719.

https://doi.org/10.1182/blood.V120.21.1719.1719

Published: 2012

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Blood (2011) 118 (21): 2790.

https://doi.org/10.1182/blood.V118.21.2790.2790

Published: 2011

Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Blood (2010) 116 (21): 1880.

https://doi.org/10.1182/blood.V116.21.1880.1880

Published: 2010

Journal Articles

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

Lionel Ades, MD, Aspasia Stamatoullas, MD, Emmanuel Raffoux, MD, Thomas Prebet, MD, Pascal Lenain, MD, Romain Guieze, MD, Mathilde Hunault, MD, Eric Wattel, MD, PhD, Laurence Stalnikiewicz, MD, Krimo Bouabdallah, MD, Vincent Levy, MD, PhD, Norbert Vey, MD, PhD, Herve Dombret, MD, PhD, Simone Boehrer, MD, PhD, Claude Gardin, MD, Pierre Fenaux, MD, PhD

Blood (2009) 114 (22): 1049.

https://doi.org/10.1182/blood.V114.22.1049.1049

Published: 2009

Journal Articles

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, MD, PhD, Lorenzo Galluzzi, phD, Lionel Ades, MD, Celine Fouassier, Claude Gardin, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2009) 114 (22): 3813.

https://doi.org/10.1182/blood.V114.22.3813.3813

Published: 2009

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 2649.

https://doi.org/10.1182/blood.V108.11.2649.2649

Published: 2006

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 856.

https://doi.org/10.1182/blood.V108.11.856.856

Published: 2006

Journal Articles

In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.

Kai Uwe Chow, MD, Daniel Nowak, Soo-Zin Kim, MD, Bernd Schneider, Martina Komor, Simone Boehrer, MD, Paris S. Mitrou, MD, Dieter Hoelzer, Eckhart Weidmann, Wolf-Karsten Hofmann

Blood (2004) 104 (11): 2273.

https://doi.org/10.1182/blood.V104.11.2273.2273

Published: 2004

Journal Articles

Overexpression of Par-4 Increases TRAIL-Induced Apoptosis in Neoplastic Lymphocytes by Diminishing Expression of Inhibitors-of-Apoptosis-Proteins and by Enforcing Activation of Initiator- and Executionercaspases.

Simone Boehrer, MD, Daniel Nowak, Dieter Hoelzer, MD, Paris S. Mitrou, Kai Uwe Chow

Blood (2004) 104 (11): 4329.

https://doi.org/10.1182/blood.V104.11.4329.4329

Published: 2004

NARROW

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.

Overexpression of Par-4 Increases TRAIL-Induced Apoptosis in Neoplastic Lymphocytes by Diminishing Expression of Inhibitors-of-Apoptosis-Proteins and by Enforcing Activation of Initiator- and Executionercaspases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only